• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Eli Lilly's mirikizumab improves fatigue in patients with Crohn's disease in...

cafead

Administrator
Staff member
  • cafead   May 26, 2021 at 11:52: PM
via Eli Lilly reports data from Phase 2 SERENITY study evaluating mirikizumab compared to placebo in patients with moderately to severely active Crohn's disease (CD) at 12 weeks.

article source